Calendar Year Performance 2015Calendar Year Performance 2016Calendar Year Performance 2017Calendar Year Performance 2018Calendar Year Performance 2019Calendar Year Performance 2020Calendar Year Performance 2021Calendar Year Performance 2022Calendar Year Performance 2023Calendar Year Performance 2024
-
-
-
-
+ 15.9 %
+ 19.9 %
+ 29.1 %
- 23.7 %
+ 23.8 %
+ 22.6 %
Net Asset Value
205.91 €
Asset Under Management
548 M €
Net Equity Exposure28/02/2025
91.1 %
SFDR - Fund Classification
Article
9
Data as of: Feb 28, 2025.
Data as of: Mar 5, 2025.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.
Global equities started the year strongly, with Europe notably outperforming the US.
The arrival of President Trump had a positive impact on the equities markets, but the rise of the Chinese artificial intelligence company DeepSeek raised concerns for players in the US technology sector.
From a macroeconomic perspective, data confirmed recent trends, showing a robust US economy (GDP up by 0.6% over the quarter) and a sluggish European economy with signs of improvement.
The Fed halted its easing cycle in January after three consecutive cuts. In contrast, the European Central Bank reduced its deposit rate by 25 bps in response to more moderate growth.
In Europe, gains were supported by the Financials and Consumer Discretionary sectors, driven by a solid global economic backdrop.
Performance commentary
The fund began the year with a positive performance, surpassing its reference indicator.
The healthcare sector, emerging from two years of relative underperformance, was the primary contributor to the month's performance. Our stock selection proved successful, as evidenced by the performances of Thermo Fisher Scientific (+14%) and Vertex (+14%).
Despite the DeepSeek announcement, our stock selection managed to avoid the high dispersion within the technology sector during the month. Consequently, the sector positively contributed to our performance in January.
Our European technology companies more than compensated for the decline in some US technology companies such as Nvidia. SAP and ASML were among the fund's main contributors.
Similarly, the luxury goods sector rebounded well following the European markets, benefiting our main conviction in the sector: Hermès.
Conversely, our consumer staples companies underperformed in the context of a still robust global economy.
Outlook strategy
The 2024 earnings season has strated. Given the high valuations in the US, tolerance for disappointment is limited. Therefore, it seems crucial for us to focus on quality companies with strong profitability.
This cautious approach is reflected in our portfolio adjustments and sector allocations, which continue to lean towards a defensive strategy.
We continue to hold a significant proportion of our fund in pharmaceuticals, medical devices, and life sciences, confident in their long-term potential despite two years of underperformance relative to the market.
During the month, we also added two new positions to our fund: Equifax and Prysmian. These companies are perfectly aligned with our investment process, both in extra-financial and financial criteria. They provide us with exposure to the credit agencies and energy and telecoms cable production sub-sectors.
Carmignac Portfolio Grandchildren is an intergenerational Fund that focuses on high-quality companies to help investors build capital not only for themselves, but also for future generations.
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performance is shown net of fees (excluding any subscription fees payable to the distributor). Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.
Unsupported browserWe've noticed that your browser is no longer supported. To ensure optimal performance and security while using our website, we recommend updating your browser or other relevant software. Thank you for your understanding!
Market environment